Dedicated to Conquering Heart Failure
A clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-fibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease
COVID-19 and CVD
Cardiol received clearance from the FDA for its IND application to commence a Phase II/III clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history, or risk factors for, cardiovascular disease (CVD).
Learn More
Acute Myocarditis
Cardiol received clearance from the FDA for its IND application for a Phase II international trial CardiolRx™ in acute myocarditis, which remains a leading cause of sudden cardiac death in people under 35 years of age.
Learn More
Heart Failure
Committed to conquering a serious condition that affects more than 26 million people globally.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis
May 17, 2022
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-label Pilot Study of CardiolRx™ for Recurrent Pericarditis
IN THE MEDIA
In a Fireside Chat hosted by Steve Grasso, CEO of Grasso Global Inc. and an advisor to the Company, Cardiol Therapeutics President and Chief Executive Officer, David Elsley, discusses Cardiol’s outlook for 2022 and provides further details on the company’s clinical trials.
TSX:CRDL NASDAQ:CRDL
